CD274
ENSG00000120217
Target class
Unclassified protein
Chromosome
9
Approved drugs
5
Clinical candidates (approved and in development)
13
- Approved drugs
- 5
- Clinical candidates (approved and in development)
- 13
- Chemical probe available
- Yes
- Target name
- CD274
- Gene name
- CD274 molecule
- Gene symbol
- CD274
- Previous gene symbols
- PDCD1LG1
- Protein name
- Programmed cell death 1 ligand 1 (PD-L1) (PDCD1 ligand 1) (Programmed death ligand 1) (hPD-L1) (B7 homolog 1) (B7-H1) (CD antigen CD274)
- B7-H
- B7H1
- PD-L1
- PDL1
- B7-H1
- Gene biotype
- Protein coding
- Gene family
- CD molecules|Receptor ligands|V-set domain containing|C2-set domain containing|B7 family
- Target class
- Unclassified protein
- Target type
- Human gene
- Tissues expressed in
- 46
- Protein localisation evidence grade
- Supported
- Highest tissue expression
- 59.8
- Tissue specificity (Gini)
- 0.584
- Tissue specificity (tau)
- 0.954
- KEGG gene identifiers
- hsa:29126
- Protein interaction confidence
- 0.814574
- Protein interaction partners
- 94
- R-HSA-389948
- R-HSA-9701898
- R-HSA-9909620
- R-HSA-9929356
- R-HSA-9929491
- R-HSA-9931269
- R-HSA-9931295
- End position
- 5470566
- Start position
- 5450503
- Chromosome
- 9
- Strand
- Forward
- Cell membrane
- Single-pass type I membrane protein . Early endosome membrane
- Single-pass type I membrane protein . Recycling endosome membrane
- Single-pass type I membrane protein . Nucleus . Note=Associates with CMTM6 at recycling endosomes, where it is protected from being targeted for lysosomal degradation (PubMed:28813417). Translocates to the nucleus in response to hypoxia via its interaction with phosphorylated STAT3 (PubMed:32929201). .
- SUBCELLULAR LOCATION: [Isoform 1]: Cell membrane
- Single-pass type I membrane protein .
- SUBCELLULAR LOCATION: [Isoform 2]: Endomembrane system
- Single-pass type I membrane protein .
- SUBCELLULAR LOCATION: [Isoform 4]: Secreted .
- Nuclear speckles
- Nucleoplasm
- Plasma membrane
- PubMed 28813410
- PubMed 28813417
- PubMed 36232715
- PubMed 32929201
- PubMed 15780196
- PubMed 30564891
- Tissue specificity (tau)
- 0.95371
- Expression inequality (Gini)
- 0.584431
Expression in transcripts per million
- Cells - EBV-transformed lymphocytes
- 59.8
- Lung
- 24.56
- Spleen
- 15
- Artery - Aorta
- 5.11
- Pituitary
- 4.81
Expression in transcripts per million
- Cells - EBV-transformed lymphocytes59.8
- Lung24.56
- Spleen15
- Artery - Aorta5.11
- Pituitary4.81
- Heart - Left Ventricle4.77
- Thyroid4.68
- Heart - Atrial Appendage4.19
- Cervix - Ectocervix3.53
- Adipose - Visceral (Omentum)3.4
- Cervix - Endocervix3.29
- Artery - Coronary3.19
- Fallopian Tube3.18
- Whole Blood3.1
- Adipose - Subcutaneous3.08
- Uterus3.04
- Small Intestine - Terminal Ileum2.65
- Nerve - Tibial2.56
- Breast - Mammary Tissue2.37
- Vagina2.35
- Esophagus - Mucosa2.31
- Brain - Hypothalamus2.27
- Kidney - Medulla2.24
- Prostate2.23
- Ovary2.2
And 29 more, listed on the interactive page.
- GO:0002841
- GO:0006955
- GO:0007165
- GO:0007166
- GO:0031295
- GO:0032689
- GO:0032693
- GO:0032733
- GO:0034097
- GO:0035666
- GO:0042102
- GO:0046006
- GO:0046007
- GO:0050860
- GO:0050868
- GO:0070232
- GO:1903556
- GO:1905399
- GO:1905404
- GO:2000562
- GO:2001186
- GO:0000139
- GO:0005576
- GO:0005634
- GO:0005654
- GO:0005789
- GO:0005829
- GO:0005886
- GO:0012505
- GO:0016607
- GO:0031901
- GO:0055038
- GO:0070062
- GO:0003713
- GO:0005515
- GO:0048018
Related records
Trials (2,566)
- --SuPERIOR Trial--
- ......SMARTEST Trial......
- "neoBREASTIM": Atezolizumab Plus RP1 Oncolytic Immunotherapy in the NeoAdjuvant Setting of Triple-Negative Breast Cancer
- 1st Line Durvalumab in PS 2 NSCLC Patients
- 89Zr-labeled KN035 PET Imaging in Patients With PD-L1 Positive Solid Tumors
- A Clinical Study Based on FAPI-PET/CT Technology to Predict Pathological Complete Response After Neoadjuvant Chemoradiotherapy for MSS Rectal Cancer
- A Clinical Study of Adebrelimab Combined With Apatinib and Paclitaxel in Patients With Advanced Gastric Cancer.
- A Clinical Study of Adebrelimab in Combination With SHR-8068 and Chemoradiotherapy as Perioperative Therapy for Locally Advanced Rectal Cancer
- A Clinical Study of Cobimetinib Administered in Combination With Niraparib, With or Without Atezolizumab to Patients With Advanced Platinum-sensitive Ovarian Cancer
- A Clinical Study of Gocatamig (MK-6070) and Infinatamab Deruxtecan (MK-2400) in People With Small Cell Lung Cancer (MK-6070-003)
- A Clinical Study of IMC-001 for Injection in Improving Atherosclerotic Plaque Stability in Patients With Acute Coronary Syndrome.
- A Clinical Study of Immunotherapy Combined With Chemotherapy and Anti-angiogenic Therapy in Operable NSCLC
- A Clinical Study of PD-L1 Antibody ZKAB001 Combined With Capecitabine in Resected Biliary Tract Cancer
- A Clinical Study of PD-L1 Antibody ZKAB001(Drug Code) in Limited Stage of High-grade Osteosarcoma
- A Clinical Study of PD-L1 Antibody ZKAB001（Drug Code） in Locally Advanced and Metastatic Urothelial Carcinoma
- A Clinical Study of PD-L1 Antibody ZKAB001（Drug Code） in Recurrent or Metastatic Cervical Cancer
- A Clinical Study of QL1706 Combined With Chemotherapy as Neoadjuvant Therapy for High-Risk Locally Advanced Cervical Cancer
- A Clinical Study of Recombinant Human Vascular Endothelial Inhibitor in Combination With PRaG for Advanced Refractory Non-small Cell Lung Cancer
- A Clinical Study of SHR-1316 (SC) Combined With Carboplatin and Etoposide as First-line Treatment for Extensive Stage Small Cell Lung Cancer
- A Clinical Study of SHR-8068 Combined With Adebrelimab and Bevacizumab Versus Sintilimab or Atezolizumab Combined With Bevacizumab for the Treatment of Advanced Hepatocellular Carcinoma
Drugs (13)
- Adebrelimab Programmed cell death 1 ligand 1 inhibitor
- Atezolizumab Programmed cell death 1 ligand 1 inhibitor
- Avelumab Programmed cell death 1 ligand 1 other
- Bintrafusp alfa Programmed cell death 1 ligand 1 binding agent
- Cosibelimab Programmed cell death 1 ligand 1 inhibitor
- Danburstotug Programmed cell death 1 ligand 1 inhibitor
- Durvalumab Programmed cell death 1 ligand 1 inhibitor
- Envafolimab Programmed cell death 1 ligand 1 binding agent
- Erfonrilimab Programmed cell death 1 ligand 1 inhibitor
- INCB-086550 Programmed cell death 1 ligand 1 inhibitor
- Pacmilimab Programmed cell death 1 ligand 1 binding agent
- Socazolimab Programmed cell death 1 ligand 1 inhibitor
- Sugemalimab Programmed cell death 1 ligand 1 binding agent